Metabolomics in Nephrology: Unraveling Metabolic Pathways in Disease

Metabolomics has emerged as a powerful tool in nephrology, enabling researchers to unravel intricate metabolic pathways underlying various renal diseases and providing insights into disease mechanisms, biomarker discovery, and therapeutic targets. By comprehensively profiling small molecule metabolites present in biological samples like urine, blood, and tissue, metabolomics offers a holistic view of metabolic dysregulation associated with kidney dysfunction. In chronic kidney disease (CKD), metabolomics has identified metabolic signatures associated with disease progression, renal fibrosis, and complications such as cardiovascular disease and mineral bone disorders. Furthermore, metabolomic profiling facilitates the identification of novel biomarkers for early detection, risk stratification, and monitoring of kidney diseases. Moreover, metabolomics-guided interventions aim to modulate metabolic pathways implicated in renal pathology through dietary interventions, pharmacological agents, and lifestyle modifications, paving the way for personalized medicine approaches in nephrology. As our understanding of renal metabolism continues to evolve, metabolomics holds immense promise in advancing nephrology research, ultimately leading to improved diagnostics, treatments, and outcomes for patients with kidney diseases.

    Related Conference of Metabolomics in Nephrology: Unraveling Metabolic Pathways in Disease

    March 17-18, 2025

    9th Global Summit onNephrology, Urology and Kidney Transplantation

    Singapore City, Singapore
    March 24-25, 2025

    21st World Nephrology Conference

    Amsterdam, Netherlands
    May 26-27, 2025

    29th European Nephrology Conference

    Rome, Italy
    June 23-24, 2025

    14th International Conference on Nephrology & Therapeutics

    Aix-en-Provence, France

    Metabolomics in Nephrology: Unraveling Metabolic Pathways in Disease Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in